Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...

With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...

While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance ...

Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like ...

In vivo CAR-T has attracted significant attention from venture capital and the pharmaceutical industry. By offering the ...

This year's catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill.

Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval ...

Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, ...

Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...

Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.

The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...

If they work together to implement drug pricing reforms in Japan, it would help revive the island nation’s stagnating life ...